Cipla Partners with Qilu for US Launch of Keytruda Biosimilar

Key Facts

In a move reflecting the growing shift toward affordable oncology treatments, India's Cipla has announced an exclusive partnership with China's Qilu Pharmaceutical. Under the agreement, Cipla's U.S. subsidiary will license a biosimilar version of Merck & Co.'s blockbuster cancer drug, Keytruda. This strategic partnership aims to capture a significant share of the U.S. oncology market by offering lower-cost alternatives to high-value biological therapies.

The collaboration comes as market participants monitor the valuation of major pharmaceutical players; per market data, Merck (MRK) closed at $151.64 on September 2, 2026. Meanwhile, its London-listed shares (0QAH.L) stood at 153.06 GBP at the close of September 3, 2026, and the German listing (6MK.DE) closed at 131.12 EUR. These price levels provide a baseline for the sector as Cipla and Qilu prepare to challenge the market dominance of established oncology treatments.

Looking ahead, the success of this venture will depend on regulatory timelines and the competitive landscape for biosimilars in the United States. Investors are also weighing broader industrial performance, noting that India's industrial production grew by 6.7% year-on-year as of August 28, 2026, which underscores the robust manufacturing backdrop for Indian pharmaceutical giants expanding into global markets.